Myocardial fibrosis as a risk stratifier for sudden arrhythmic death

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 8, 2011, Pages 951-953

  Sovari, Ali A ^a   Karagueuzian, Hrayr S ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

afterpotential; late gadolinium; myocardial fibrosis; re entry; serum markers of fibrosis enhancement; sudden cardiac death; ventricular arrhythmia

Indexed keywords

BIOLOGICAL MARKER;

CARDIOVASCULAR MAGNETIC RESONANCE; EARLY AFTERDEPOLARIZATION; HEART DEPOLARIZATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; REVIEW; RISK ASSESSMENT; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; DEATH, SUDDEN, CARDIAC; FIBROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PRACTICE GUIDELINES AS TOPIC; RISK;

EID: 80052490420     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.103     Document Type: Review

References (29)

1. Mehra R. Global public health problem of sudden cardiac death. J. Electrocardiol. 40(Suppl. 6), S118-S122 (2007).
2. Garfinkel A, Chen PS, Walter DO et al. Quasiperiodicity and chaos in cardiac fibrillation. J. Clin. Invest. 99(2), 305-314 (1997).
3. Weiss JN, Qu Z, Chen PS, Lin SF et al. The dynamics of cardiac fibrillation. Circulation 112(8), 1232-1240 (2005).
4. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 97(15), 1514-1521 (1998).
5. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J. Clin. Invest. 115(9), 2305-2315 (2005).
6. Sovari AA. postinfarct cardiac remodeling and ventricular arrhythmias. In:Myocardial Ischemia; Causes, Symptoms, and Treatment. First Edition . Vukovik D, Kiyan V (Eds). Nova Science Publishers, NY, USA, 269-277 (2010).
7. Sovari AA, Morita N, Weiss JN, Karagueuzian HS. Serum transforming growth factor-b1 as a risk stratifier of sudden cardiac death. Med. Hypotheses 71(2), 262-265 (2008).
8. Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart 89(10), 1255-1256 (2003).
9. Fielitz J, Hein S, Mitrovic V et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J. Am. Coll. Cardiol. 37(5), 1443-1449 (2001).
10. Wu TJ, Ong JJ, Hwang C et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J. Am. Coll. Cardiol. 32(1), 187-196 (1998).
11. Morita N, Sovari AA, Xie Y et al. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 297(5), H1594-H1605 (2009).
12. Sovari AA. Oxidative stress promotes ventricular fibrillation at the early stages of hypertension: role of Ca2+/CaM kinase-II. Heart Rhythm 7, 5-23 (2010).
13. Morita N, Lee JH, Bapat A et al. Glycolytic inhibition causes spontaneous ventricular fibrillation in aged hearts. Am. J. Physiol. Heart Circ. Physiol. 301(1), H180-H191 (2011).
14. Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ. Res. 101(8), 755-758 (2007).
15. Ono N, Hayashi H, Kawase A et al. Spontaneous atrial fibrillation initiated by triggered activity near the pulmonary veins in aged rats subjected to glycolytic inhibition. Am. J. Physiol. Heart Circ. Physiol. 292(1), H639-H648 (2007).
16. Schultz JJ, Witt SA, Glascock BJ et al. TGF-b1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest. 109(6), 787-796 (2002).
17. Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J. Mol. Cell. Cardiol. 33(6), 1191-1207 (2001).
18. Li G, Borger MA, Williams WG et al. Regional overexpression of insulin-like growth factor-I and transforming growth factor-b1 in the myocardium of patients with hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg. 123(1), 89-95 (2002).
19. Sanderson JE, Lai KB, Shum IO, Wei S, Chow LT. Transforming growth factor-b(1) expression in dilated cardiomyopathy. Heart 86(6), 701-708 (2001).
20. Mitchell JA, Ventura HO, Mehra MR. Early recognition and treatment of hypertensive heart disease. Curr. Opin. Cardiol. 20(4), 282-289 (2005).
21. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manage. 4(3), 575-596 (2008).
22. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc. Health Risk Manage. 4(3), 575-596 (2008).
23. Ito N, Ohishi M, Yamamoto K et al. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am. J. Hypertens. 20(7), 792-799 (2007).
24. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 133(5), 687-694 (2001).
25. Villarreal F, Zimmermann S, Makhsudova L et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol. Cell. Biochem. 251(1-2), 17-26 (2003).
26. Maron MS. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J. Cardiovasc. Transl. Res. 2(4), 415-425 (2009).
27. Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 48(10), 1977-1985 (2006).
28. Wu KC, Weiss RG, Thiemann DR et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 51(25), 2414-2421 (2008).
29. Iles L, Pfluger H, Lefkovits L et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter- defibrillators for primary prevention of sudden cardiac death. J. Am. Coll. Cardiol. 57(7), 821-828 (2011). (Pubitemid 28112428)